Extention of Collaboration

Sareum Holdings PLC
30 July 2007


For immediate release                                               30 July 2007



                              SAREUM HOLDINGS PLC
                          ("Sareum" or the "Company")

                  Collaboration Extension with H. Lundbeck A/S



Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that, based on the success of the previous
agreement announced in August 2006, H. Lundbeck A/S (Copenhagen: LUN) have
chosen to extend their collaborative agreement with Sareum for a further 12
months.

Under the terms of this agreement, Sareum will continue to apply its skills in
high throughput protein expression, purification and structure determination to
assist Lundbeck's scientists in developing new and improved therapeutics to help
patients suffering from diseases of the central nervous system, Lundbeck's key
drug discovery focus area.

In return, Sareum will receive research fees and success milestone payments.
Financial terms of the agreement were not disclosed.

Commenting on the agreement, Sareum's Chief Executive Officer, Dr Tim Mitchell,
said: "We are very pleased to have successfully supported Lundbeck's key drug
discovery programs over the last 12 months, and look forward to continuing this
successful relationship over the next year. Delivering on long term
relationships with important customers such as Lundbeck is a key component of
our business strategy and further evidence of our success in being a partner of
choice for structure-based drug discovery."





For further information:


Sareum Holdings                                       01223 497700
Tim Mitchell, Chief Executive Officer

Buchanan Communications                               020 7466 5000
Tim Anderson, Mary-Jane Johnson

Grant Thornton Corporate Finance                      020 7383 5100
Philip Secrett, Colin Aaronson




Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk





                      This information is provided by RNS
            The company news service from the London Stock Exchange